Cancer Genetics Inc (CGIX) Releases Earnings Results, Beats Expectations By $0.05 EPS

Cancer Genetics Inc (CGIX) reported quarterly earnings results on Tuesday, Aug-9-2016. The company said it had a profit of $-0.28 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.05. Analysts had a consensus of $-0.33. The company posted revenue of $7.00 million in the period, compared to analysts expectations of $6.50 million. The company’s revenue was up 67.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.51 EPS.

Cancer Genetics Inc opened for trading at $2.1499 and hit $2.2 on the upside on Monday, eventually ending the session at $2.19, with a gain of 2.82% or 0.06 points. The heightened volatility saw the trading volume jump to 58,922 shares. Company has a market cap of $30 M.

In a different news, on Mar 18, 2016, Howard Mcleod (director) purchased 1,000 shares at $2.71 per share price. According to the SEC, on Mar 17, 2016, Panna Sharma (CEO) purchased 1,500 shares at $2.59 per share price. On Mar 17, 2016, Michael J. Welsh (director) purchased 40 shares at $2.42 per share price, according to the Form-4 filing with the securities and exchange commission.

Cancer Genetics Inc. is an oncology diagnostics company focused on developing commercializing and providing DNA-based tests and services. The business is based on demand for DNA-based diagnostic services from three main sectors including cancer centers and hospitals biotechnology and biopharmaceutical companies and the research community. Its clinical offerings include its portfolio of proprietary tests targeting hematological urogenital and HPV-associated cancers in conjunction with ancillary non-proprietary tests. Biopharma services include laboratory and testing services performed for biopharmaceutical companies engaged in clinical trials. Discovery services provide the tools and testing methods for companies and researchers seeking to identify new DNA-based biomarkers for disease.

Cancer Genetics Inc

Leave a Reply

Cancer Genetics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Cancer Genetics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.